Document:

exv10w1

 

Exhibit 10.1

LICENSE AGREEMENT

     This License Agreement (“Agreement”) is entered into as of March 15, 1988 by and between
CYBERONICS, INC., a Delaware corporation, having a principal place of business at 827 W. Main
Street, League City, TX 77573 (“Licensee”), and DR. JACOB ZABARA, an individual residing at 200
Locust Street, #22F, Philadelphia, PA 19106 (“Licensor”).

     WHEREAS, Licensor owns a patent relating to Neurocyberenetic Prosthesis Technology (U.S.
Patent No. 4,702,254) and other pending patent applications and know-how, and technology relating
thereto (collectively referred to as the “Technology”); and,

     WHEREAS, Licensee wishes to obtain all exclusive license under the Licensed Patents as
hereinafter defined and under the Technology generally to further test and develop the Technology
and to manufacture and market products based on such Technology upon the terms and conditions
hereinafter set forth;

     NOW, THEREFORE, in consideration of the promises and of the mutual covenants hereinafter
contained, the parties agree as follows:

     1. Definitions.

          (a) The term “Licensed Patents,” as used in this Agreement, shall mean and include both
individually and collectively the United States and foreign patents and patent applications listed
in Schedule A attached to this Agreement, such additional United States and foreign patent
applications acquired by Licensor on improvements and variations upon inventions disclosed in said
listed applications or other inventions “in the field of nerve stimulation, and such additional
patent applications as may be filed by Licensor pursuant to Section 7 of this Agreement, all
Letters Patent which shall issue on said applications and any division thereof, and all reissues,
continuations, or extensions of said Letters Patent.

          (b) The term “Product,” as used in this Agreement, shall mean a product or portion of a
product that (i) embodies a device invention claimed in a Licensed Patent (or which had been
“claimed” in a Licensed Patent which has been declared invalid), or (ii) which is specifically
intended to be used to practice a method claimed in a Licensed Patent (or which had been “claimed”
in a Licensed Patent which has been declared invalid) and which is manufactured and sold by or for
Licensee (or its sublicensees); provided that at the time and in the territory of manufacture or
sale of such Product a Licensed Patent is pending or in force claiming such device or method (or
such device or method had been “claimed” in a Licensed Patent previously valid in the territory of
manufacture or sale but which has been declared invalid).

     2. Licensor’s Representations & Warranties. Licensor represents and warrants that:

          (a) He owns the Licensed Patents and has the legal power and authority to extend the rights
granted to Licensee pursuant to this Agreement and he has not assigned, licensed, pledged or
compromised the Licensed Patents or made any commitments or offers inconsistent with or in
derogation of the rights created by this Agreement.

 

 

          (b) Neither the Licensed Patents nor any claims contained therein have been declared invalid
or unenforceable and to the best of Licensor’s knowledge there are no patent infringement suits or
asserted patent infringement claims pertaining to the Licensed Patents and there are no suits or
claims attacking the validity of any Licensed Patent, and Licensor knows of no basis for any such
claim.

          (c) Licensor has no knowledge of any information likely to have a material effect on the
validity or enforceability of any Licensed Patent or any claim thereof which was not disclosed to
the Patent Office of the respective countries in which Patent Applications were filed during the
prosecution of the application from which any Licensed Patent matured or, with respect to pending
applications, from which any Licensed Patent may mature.

     3. License.

          (a) Licensor hereby grants to Licensee, and Licensee hereby accepts from Licensor, upon the
terms and conditions herein after specified, the exclusive, worldwide right and license under the
Licensed Patents and Technology to further test and develop the Technology, to make, to have made,
to use, to sell, to lease, to implant, and to have implanted and otherwise dispose of Products and
to sublicense the rights created hereby pursuant to the terms of Section 5 hereof. Such license
shall be perpetual unless this Agreement is terminated pursuant to Section 3.0 hereof.

          (b) Any person, firm, or corporation purchasing Products from Licensee or any Sublicensee
hereunder, and its successors and assigns, shall automatically enjoy a royalty-free right under the
Licensed Patents to implant and/or have implanted and to use the particular Product, and to
manufacture, purchase, implant, and use any auxiliary products which may be necessary or desirable
to provide a complete implant.

     4. Royalties, Records and Reports.

          (a) Licensee agrees to pay to Licensor, in consideration for the license granted pursuant to
this Agreement, royalties on the Net Sales Value (as hereinafter defined) of all Products sold
during the term of this Agreement at the rate of six percent (6.0%) on the first $12,000,000 of Net
Sales Value and three percent (3.0%) on all Net Sales Value after said $12,000,000, cumulative and
not annual, for the life of U.S. Patent No, 4,702,254, including any extensions, renewals,
continuations, divisions, or continuations-in-part thereof. Upon expiration of the last to expire
of U.S. Patent No. 4,702,254 (including any extensions or renewals thereof) or any continuation,
division or continuation-in-part thereof, the royalty rate payable pursuant to this Section 4(a)
shall be reduced to two percent (2.0%) on the first $12,00.0,000 of Net Sales Value and one percent
(1.0%) on all Net Sales Value after said $12,000,000, cumulative and not annual. It is understood
and agreed that Licensee shall have no obligation to make any payment to Licensor under this
Section 4(a) or Section 4(d) from and after the date on which all of the Licensed Patents
(including any extensions or renewals thereof) have expired or have been declared invalid by any
judicial decree, order or final judgment beyond right of further appeal, except royalties at the
percentile rate specified in this Section 4(a) or Section 4(b), as the case may be, on the Net
Sales Value of Products sold under the license created by Section 3 of this

-2-

 

Agreement prior to such date, and upon such date the license granted by Section 3 hereof shall
be fully paid.

          (b) If U.S. Patent No. 4,702,254 and all continuations, divisions, and continuations-in-part
thereof are held invalid by any judicial decree, order or final judgment beyond further right i
of appeal, the-percentile rate at which royalties shall be payable to Licensor pursuant to Section
4(a) shall be retroactively reduced to two percent (2.0%) on the first $12,000,000 of Net Sales
Value and one percent (1.0%) on all Net Sales Value after said $12,000,000 with respect to Products
sold after the filing of a claim in a court of competent jurisdiction which claim results in the
invalidation of U.S. Patent No. 4,702,254 and all continuations, divisions and
continuations-in-part thereof (the “Claim”).

          (c) In the event of U.S. Patent No. 4,702,254 .and all continuations, divisions and
continuations-in-part thereof being declared invalid, and notwithstanding anything to the contrary
contained herein, no further royalty payments shall be made to Licensor until such time as the
aggregate royalties payable on products sold after filing of the Claim at the percentile rate
specified in Section 4(b) are equal to the actual aggregate royalties already paid to Licensor on
products sold after filing of the claim, at which time royalty payments as provided in this Section
4 shall resume. The right created by this Section 4(c) shall be a right to recover excess
royalties paid during the pendency of the claim from future royalties payable to Licensor hereunder
only; Licensee shall have no right, claim or cause of action against Licensee to recover such
excess royalties from Licensor.

          (d) Licensor agrees to pay Licensee a minimum royalty of $36,000 per year ($12,000 per year if
the events specified in Section 4(b) occur), payable on a monthly basis until a Product is first
sold and on a quarterly basis thereafter. Payments made pursuant to this Section 4(d) shall be
paid at the beginning of the month or quarter, as the case may be, and shall be deducted from any
royalties payable pursuant to Section 4(a) and shall not constitute an additional royalty
obligation of Licensee.

          (e) The term “Net Sales Value,” as used in this Section 4, shall mean the full amount actually
received by Licensee or its sublicensees (exclusive of sales by Licensee to its sublicensees) for
Products sold by Licensee or its sublicensees to customers less the sum of the following, where
applicable:

     (i) Discounts allowed, commissions paid in lieu of trade discounts, and
commissions paid to independent sales representatives or agents, in the amounts
customary in the trade;

     (ii) Sales and/or use taxes (or other taxes equivalent thereto), duties or any
other taxes or levies directly imposed by any governmental authority upon and with
reference to particular sales;

     (iii) Outbound transportation costs prepaid or allowed by way of freight
equalization or otherwise;

     (iv) Cartons, packing, and crating charged separately ;

-3-

 

     (v) Amounts refunded, allowed, or credited in connection with shortages,
returns, or defective, articles;

          (f) Where proceeds from the sale of Products are received in currency other than United States
Dollars, the Net Sales Value of such foreign sales shall be the U.S. Dollar equivalent of such
proceeds determined by multiplying the foreign currency actually received by the applicable
exchange rate in effect on the last day in the quarter in which such proceeds were received, as
published in the Wall Street Journal for such date.

          (g) Only one royalty shall be payable on a Product at the applicable percentile rate specified
in Section 4(a) or 4(b), as the case may be, regardless of the number of Licensed Patents or use of
Technology under which such Product has been manufactured, used or sold. In those cases where a
Product is sold as a part of an article which includes additional materials or components, the
production of which does not use the inventions of the Licensed Patents, the Net Sales Value shall
be based on the sales price at which Licensee would sell the Product independently of such other
materials or components in an arm’s length transaction.

          (h) Licensee agrees to keep full, true, and accurate records and books of account containing
all particulars which may be necessary to show the royalties payable to Licensor. Such books of
account shall be kept at Licensee’s principal place of business and shall be available, upon thirty
(30) days notice, for inspection during business hours, by independent auditors reasonably
acceptable to Licensee appointed and paid by Licensor provided, however, that if upon audit it is
determined that Licensor is entitled, to., receive an additional royalty amount in excess of five
percent (5%) over the amount previously paid during the period subject to “audit, then Licensee
shall pay the reasonable fees and expenses of such independent auditors. Such records shall be
retained by Licensee for a period of six (6) years following the end of the calendar year to which
they pertain; provided, however, that Licensor’s right to inspect such records pursuant to this
Section 4(h) shall be limited to the right to inspect records pertaining to the two-year period
ending on the close of the calendar quarter immediately preceding such inspection. Only one such
inspection shall be made in any calendar year. The auditors shall disclose to Licensor only the
gross sales value of Products sold, the deductions therefrom, the Net Sales Value thereof, and the
amount of royalties due and payable to Licensor thereon, along with any necessary supporting
evidence. Any information obtained by the auditors from any such inspection shall be kept
confidential by Licensor and the auditors and shall be used only for the purpose of determining the
correctness of the statements of Net Sales value and royalties due and payable to Licensor. The
auditors shall be employed expressly upon such terms and conditions.

          (i) Licensee agrees that on or before the 60th day after the close of each of its quarterly
accounting periods throughout the term of this Agreement, Licensee shall forward to Licensor a
statement, certified by an Officer of Licensee, of the receipts for Products sold by Licensee for
which payment is received during the accounting period preceding the period in which each such
statement is rendered, the aggregate in each category of deductions which have been made therefrom
pursuant to the provisions of section 4(e) above, and the royalties payable thereon. Licensee
shall concurrently forward to Licensor a Statement of the receipts for Products sold by
sublicensees for which Licensee received royalty or other licensing fees from such sublicensees
during the accounting period preceding the period in which each such statement is

-4-

 

rendered, the aggregate in each category of deductions which have been made therefrom pursuant
to Section 4(e) above, and the royalties payable thereon. Licensee shall simultaneously pay to
Licensor the amount of royalties due.

          (j) The parties agree that any subsequent downward adjustments of Licensee’s and its
sublicensees’ receipts from any particular sale of Products upon which royalties have been paid,
due to Product failure or inadequacy, cancellation of purchase orders or contracts, or any other
event causing Licensee to make a financial refund to its customers, either in whole or in part,
will be credited against any future receipts on which royalties become payable.

     5. Sublicensing.

          (a) Licensee shall have the exclusive right under the Licensed Patents to grant sublicenses to
others provided, however, that with respect to Products sold by any such sublicensee, Licensee
shall pay to Licensor royalties equal to the royalties that would have been payable with respect to
such Product sales had such sales been made by Licensee. The Net Sales Value of sales made by any
sublicensees shall be aggregated with the Net Sales Value of Sales made by Licensee for
determination of the applicable royalty rate payable pursuant to Section 4(a) or 4(b), as the case
may be.

          (b) Licensee shall consult with Licensor regarding any prospective sublicensees.
Notwithstanding the foregoing, the granting by Licensee of sublicenses under the Licensed Patents
shall be in the sole discretion of Licensee, and Licensee shall have the sole power to determine
whether or not to grant sublicenses, to whom such sublicensees shall be granted and the royalty
rates and terms and conditions of such sublicenses.

     6. Assignment.

          (a) This Agreement and the licenses and rights hereunder are not assignable by either party
without the prior written consent of the other party, which consent will not be unreasonably
withheld; provided, however, that without obtaining Licensor’s consent, Licensee may assign its
rights and obligations hereunder to a successor in interest who acquires substantially all of the
business of Licensee whether by sale of substantially all of the assets, sale of stock, merger or
other form or corporate reorganization.

          (b) This Agreement shall inure to the benefit of and be binding upon Licensor and Licensee,
and their respective successors and assigns.

     7. Future Filings; Patent Expenses.

          (a) In the event that Licensee should wish Licensor to file any patent applications
corresponding to any of the Licensed patents in specific countries other than those enumerated in
Schedule A or file any patent applications on improvements and variations upon inventions disclosed
in the Licensed Patents or other inventions in the field of nerve stimulation, it shall advise
Licensor in writing, naming such countries or improvements, variations or inventions, as the case
may be. Licensor shall thereupon file patent applications as requested. All such patent
applications and patents shall be filed in the name of and, be the property of

-5-

 

Licensor and shall be included in the Licensed Patents. Licensee shall pay the reasonable
expenses, including reasonable fees for patent counsel, for filing, prosecuting, and paying
annuities or applicable maintenance fees on such requested patent applications, on any patent
applications relating to the Technology pending as of the date thereof and shall pay the issuance
fee of and any applicable maintenance fee on any patent issued thereon. In the event Licensee
elects to discontinue pursuing any patent application or applications (whether or not such
applications have been prepared or filed) it shall so notify Licensor in writing and Licensor shall
discontinue pursuing such application or applications (or may pursue such application or
applications at its own expense); provided, however, that Licensee shall pay the reasonable
expenses, including reasonable fees for patent counsel, incurred prior to Licensee notifying
Licensor of its election not to pursue an application or applications. Licensor further agrees
that he will not file any patent applications relating to the Licensed Patents, the Technology or
the field of nerve stimulation without the consent of Licensee; provided, however, that if such
consent is withheld, Licensor may file such application but shall bear all expenses associated with
such filing or any patent issuing thereon.

          (b) In the event that Licensee notifies Licensor that Licensee would like Licensor to file any
patent applications pursuant to Section 7(a) and Licensor fails to take reasonable steps within a
reasonable amount of time to prepare and file such application or applications, Licensee reserves
the right hereunder to retain its own patent counsel to prepare and prosecute any such patent
applications, and Licensor hereby agrees to assist and cooperate with Licensee’s patent counsel in
the preparation and prosecution of such patent applications; provided, however, that
notwithstanding Licensee’s retention of patent counsel, Licensee shall pay the reasonable fees of
Licensor’s patent counsel actually incurred in connection with reviewing any patent applications
prepared by Licensee’s patent counsel.

     8. Covenants.

          (a) Licensor shall promptly furnish Licensee with copies of all applications for Letters
Patent licensed hereunder and shall keep Licensee promptly informed as to their prosecution,
sending Licensee copies of Patent Office actions and amendments to such applications.

          (b) Licensor covenants that for the term of this Agreement he will use his best efforts to
renew and maintain all Licensed Patents (at Licensee’s expense as provided in Section 7 hereof).

          (c) Licensor covenants that for the term of this Agreement he will not assign, license, pledge
or compromise the Licensed Patents nor make any commitments or offers inconsistent with or in
derogation of the rights created by this Agreement.

          (d) Licensee covenants that for the term of this Agreement it will use its best efforts to
develop and market a Product or Products.

     9. Term. This Agreement shall expire at the earlier of (i) the end of the full term
of each Letters Patent included in the Licensed Patents or (ii) at such time as all of the Licensed
Patents shall have been declared invalid by any judicial decree, order or final judgment beyond

-6-

 

further right of appeal; provided, however, that the license created hereby shall survive
expiration of this Agreement as provided in Section 3(a) hereof.

     10. Termination.

          (a) This Agreement may be terminated by Licensee as follows:

     (i) For the first three (3) years of this Agreement, Licensee may terminate
this Agreement without cause on the first, second or third anniversary of execution
hereof by Licensee provided Licensee gives written notice to Licensor of its
intention to terminate no later than sixty (60) days before such anniversary.

     (ii) If this Agreement is not terminated within the first three years as set
forth above, this Agreement shall run for successive three-year periods starting
from the third anniversary of execution thereof by Licensee and may not be
terminated by Licensee without cause during such three-year periods but may be
terminated without cause by Licensee at the end of each such three-year period
provided Licensee gives notice of its intention to terminate no later than sixty
(60) days before the expiration of such three-year period;

     (iii) In addition to the foregoing, this Agreement may be terminated by
Licensee in the event that Licensor shall have materially breached any provision
hereof, provided that Licensee shall first give written notice of its intention to
terminate which notice shall state the grounds thereof and provided further that
Licensor shall have sixty (60) days to cure any alleged breach.

          (b) This Agreement may be terminated by Licensor for cause only and provided that Licensor
shall first give written notice of his intention to terminate which notice shall state the grounds
thereof. Licensee shall have sixty (60) days from receipt of any such notice to cure any alleged
breach. Subject to the provisions of Section 11 hereof, “Cause” for purposes of this Section 10(b)
shall be defined as:

     (i) Failure of Licensee to make royalty payments as provided in Section 4
hereof;

     (ii) Failure to begin feasibility clinical studies of the Technology (such as
would be permitted under the “Custom Devise” exemption of the United States Food and
Drug Administration (“FDA”)) within one (1) year of the date hereof if stimulators
developed and purchased from an independent producer are used or two (2) years from
the date hereof if a stimulator developed by Licensee is used;

     (iii) Failure to begin formal clinical studies of the Technology (such as would
be permitted under the Investigational Device Exemption of the FDA) within three (3)
years from the date hereof;

     (iv) Failure to file a Pre-Market Approval Application with the FDA within six
(6) years from the date hereof.

-7-

 

          (c) Upon termination of this Agreement pursuant to this Section 10, all licenses, rights, and
obligations hereunder shall cease and terminate and Licensee shall immediately cease manufacturing
and selling Products; provided, however, that the licenses and rights granted under Section 3
hereof shall continue as to all Products previously manufactured during the term of this Agreement,
or actually in manufacture upon the date of termination, for the full terms of the Letters Patent
under which such Product is manufactured, provided that royalties are paid with respect to such
Products pursuant to Section 4 hereof.

     11. Force Majeure. The time by which, the conditions subsequent specified in Sections
10(b)(ii) — (iv) must be satisfied shall be extended for a period of time equal to the period of
any delay resulting from delays or difficulties arising in connection with the clinical studies
and/or obtaining requisite regulatory approval provided such delays or difficulties are due to
events beyond the control of Licensee.

     12. Marketing Requirements. Licensee shall provide with all Products such notice or
notices of the Licensed Patents reasonably contemplated to comply with the laws of the countries
under which such Letters Patent have issued.

     13. Technical Assistance. Licensor shall assist, consult, and cooperate with Licensee
in the development, design, engineering, manufacturing/testing and inspection of the Products.
Licensor shall provide such assistance to Licensee at such times and for such duration as Licensee
shall reasonably request, provided such assistance does not interfere with Licensor’s
responsibilities as a faculty member of Temple University. For two (2) years from the date of this
Agreement, such assistance shall be provided to Licensee without compensation (other than
reimbursement of out-of-pocket expenses reasonably incurred in connection with providing such
assistance). Following such initial two-year period, Licensor shall continue to provide such
assistance as Licensee may reasonably request and shall be compensated therefor as provided in the
separate consulting agreement executed concurrently herewith.

     14. Patent Enforcement. Licensee may bring any action for infringement of the
Licensed Patents either in Licensor’s name alone or jointly with Licensor and Licensor agrees to
assist Licensee in any such action upon Licensee’s request. Any such action brought by Licensee
shall be solely at Licensee’s expense, and any amounts recovered thereby shall be divided between
Licensee and Licensor as follows:

          (a) Licensee shall first recoup all expenses and legal fees expended in such action,

          (b) The amount recovered, net of Licensee’s expenses and fees as provided in Section 14(a),
shall be divided eighty percent (80%) to Licensee and twenty percent (20%) to Licensor.

     15. Public Statements.

          (a) Licensor agrees not to publish or caused to be published any article, study, analysis, or
other writing concerning the Technology or stimulation of the vagus nerve for the treatment of
epilepsy and not to deliver or permit others to deliver any oral presentation prepared by Licensor
containing information concerning the Technology or stimulation of the vagus nerve

-8-

 

for the treatment of epilepsy (such writings and presentations being referred to as “Public
Statements”) prior to the earlier of (i) three years from the date hereof, or (ii) the clinical
investigators publishing or presenting the results of the clinical studies of the Technology
conducted on the initial is patients. After such publication by the clinical investigators or
three years, whichever is earlier, Licensor shall not, for the term of this Agreement, make any
Public Statement without first obtaining the written consent of Licensee, which consent shall not
be unreasonably withheld. The restrictions on Licensor’s right to make Public statements created
by this Section 15(a) shall, terminate immediately in the event that all of the clinical
investigators withdraw from the clinical study.

          (b) Licensee agrees that Licensor may have access to technical data generated in connection
with scientific studies concerning the Technology conducted by or on behalf of Licensor and,
subject to Section 15(a), may use such data in writings or oral presentations concerning the
Technology. Licensee further agrees that Licensor will be named as a co-author in any article,
study, analysis or other writing concerning the Technology if Licensor actively participated in the
underlying research. Licensee further agrees that Licensor shall have the right to review any
article, study, analysis or other writing prepared by or on behalf of Licensee prior to
publication; provided, however, that Licensee reserves the right to publish or present any such
article, study, analysis or writing notwithstanding Licensor’s objections thereto.

     16. General.

          (a) Modification. This Agreement may be modified only by a writing signed by each
party.

          (b) Nonwaiver. The failure of any party to enforce at any time any of the provisions
hereof shall not be construed to be a waiver of the right of such party thereafter to enforce any
such provision.

          (c) Notices. Notices under this Agreement shall be sufficient only if mailed by
certified or registered United States mail, return receipt requested, or personally delivered to
the parties at their addresses first set forth above or as amended by notice pursuant to this
subsection. Notice by mail shall be deemed received three (3) days after deposit.

          (d) Entire Agreement. This Agreement terminates the letter of intent between
Licensor, Reese Terry, Cyberonics, Inc., a Texas corporation (“Cyberonics Texas”), as amended and
assigned from Cyberonics Texas to Licensee, and supersedes all proposals, oral or written, all
negotiations, conversations or discussions between or among the parties relating to this Agreement
and all past course of dealing or industry custom. The terms and conditions of this Agreement
shall prevail, notwithstanding any variance with the written instrument, submitted by any party.

          (e) Counterparts. This Agreement may be executed in one or more counterparts, each of
which shall be an original and all of which together shall constitute one and the same instrument.

-9-

 

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth
above.

	 	 	 
	LICENSOR: DR. JACOB ZABARA
	 	 
	 

	 	 
	/s/ Jacob Zabara
	 	 
	  
	 	 
	 

	 	 
	LICENSEE: CYBERONICS, INC.

     a Delaware corporation
	 	 
	 
	 	 
	/s/ Reese S. Terry, Jr.
	 	 
	  
	 	 

-10-

 

SCHEDULE A

UPDATED ATTACHMENT TO

JACOB ZABARA LICENSE AGREEMENT

December 31, 1991

	 	 	 	 	 	 	 
	 	 	 	 	 	 	Date
	4,702,254

	 	US
	 	NeuroCybernetic Prosthesis
	 	Oct. 27, 1987
	4,867,164

	 	US
	 	NeuroCybernetic Prosthesis
	 	Sept. 19, 1989
	5,0258,807

	 	US
	 	NeuroCybernetic Prosthesis
	 	June 25, 1991
	577,549

	 	Australia
	 	NeuroCybernetic Prosthesis
	 	March 3, 1989
	1,259,379

	 	Canada
	 	NeuroCybernetic Prosthesis
	 	September 12, 1989
	0,156,854

	 	Eurpoean
	 	NeuroCybernetic Prosthesis
	 	September 5, 1990
	 	 	Austria, Belgium, Switzerland, Germany, France, United
	 	 	Kingdom, Liechtenstein, Luxembourg, Netherlands, Sweden
	503,504/84

	 	Japan
	 	Application Number
	 	September 11, 1984

-11-exv10w2

 

Exhibit 10.2

LICENSE AGREEMENT

     THIS AGREEMENT (“Agreement”) dated as of August 22, 2000 (the “Effective Date”) by and
between Mitchell S. Roslin, M.D., a citizen of the United States of America residing in New York,
NY (“Licensor”), and Cyberonics, Inc., a Delaware corporation with offices in Houston, Texas
(“Licensee”).

Recitals:

     Licensee is engaged in designing, developing, investigating, testing, and marketing
specialized medical devices primarily used or to be used for treating disorders by nervous system
stimulation, and owns basic patents related to the use of nerve stimulation for eating, endocrine
and other disorders, including patents on the use of vagus nerve stimulation (VNS) to treat
obesity;

     Licensor is medical doctor licensed to practice medicine in the State of New York, and is a
co-inventor with Burke T. Barrett of Licensee and Ramesh Reddy, M.D. on a United States patent
application for bi-lateral VNS for the treatment of obesity, Serial No. 09/346,396, filed on or
about July 1, 1999, and/or continuations or divisions thereof, and a PCT counterpart application
thereof (collectively, “the ‘396 Application”), the original animal studies for which were
initiated by Licensor with participation, assistance, support, advice and devices of Licensee; and

     Licensee and Licensor desire to enter into an agreement under which Licensee will acquire
from Licensor the exclusive right and license to practice the
inventions) covered by the ‘396
Application to the fullest extent of Licensor’s right, title and interest in and to the
invention(s), and in and to all other inventions conceived, made, reduced to practice, owned or
controlled by Licensor in the field of nervous system stimulation, on the terms and conditions set
forth in this Agreement.

     In consideration of the foregoing recitals, and the mutual undertakings set forth herein,
Licensee and Licensor (collectively, “the Parties”) do hereby AGREE AS FOLLOWS:

Article I. Definitions. As used in this Agreement, terms shall have the following meanings:

     1.01 “Confidential Information” shall mean information of Licensee relating to its
business
plans, experimental products, research or development activities, financial information,
identity of
customers and key personnel, marketing and distribution, and other transactions, actual or
prospective, treated by Licensee as secret and protected as such by confidentiality or
nondisclosure
agreements or the like and by applicable marking of documents and other tangible items with
words
indicative of information of confidential or secret content and with applicable notice where
the
content is communicated orally or visually.

     1.02 “FDA” shall mean the U.S. Food and Drug Administration, which has responsibility
under the law for, among other things, establishing protocol for clinical investigation of
medical
devices and granting Investigational Device Exemption (“IDE”), determining from results of
clinical
investigation whether a medical device is safe and effective for treating a disease or
disorder, and

1

 

granting Pre-Market Approval (“PMA”) of medical devices.

     1.03 “Invention” shall mean an advance, innovation, discovery, or improvement in a product,
process, method, or technique, whether patentable or not, conceived, made, or reduced to
practice
by Licensor, alone or with others, or owned or controlled in whole or in part by Licensor, at
any time
during the term of this Agreement, in the field of nervous system stimulation.

     1.04 “Licensed Patents” shall mean United States patent application Serial No.
09/346,396
filed July 1, 1999 in the names of Mitchell Roslin and others for “Treatment of Obesity by
Bilateral
Vagus Nerve Stimulation”, and all continuations, continuations in part and divisions thereof,
all
patents issued, reissued, reexamined, and renewed (e.g., by payment of maintenance fees or
annuities,
as the case may be) thereon, and all counterparts (i.e., corresponding applications and
patents) and
equivalents (i.e., statutorily protected or designated by status of invention, characterized
as other than
a patent application or patent) thereof filed or issued in other countries (including but not
limited to
nationalizations under the Patent Cooperation Treaty (PCT) in the name (with or without
others), on
behalf, or with concurrence of Licensor; and any and all Inventions, whether or not
applications for
patent, patents or equivalents are filed thereon, and, if filed, such patent, patents or
equivalents. The
Licensed Patents as of the Effective Date hereof are set forth in Exhibit A (attached
hereto and
integrated herein), subject to modification from time to time to add newly arising, filed or
issued
Licensed Patents as provided herein.

     1.05 “Licensed Products” shall mean any and all products, devices, apparatus, and
systems,
and “Licensed Methods” shall mean any and all methods, techniques, and processes,
covered by any
claim(s) of the Licensed Patents.

     1.06 “Net Sales” shall mean gross sales of Licensed Products by Licensee or its
sublicensee(s), as the case may be, less taxes and tariffs (by whatever name they may be
designated)
imposed by governmental authorities on the manufacture, sale, importation, lease or storage of
Licensed Products and actually paid by Licensee (or its sublicensee(s)); packing and freight
charges
(including insurance costs for transportation) actually included in Licensee’s (or its
sublicensee’(s’))
invoices for Licensed Products; and credits for returns, discounts, and allowances actually
granted
by Licensee (or it sublicensee(s)) to customers for Licensed Products. In the event that a
Licensed
Product is disposed of in a transaction with a third party other than an arms length sale
between
unrelated parties, the transaction shall be treated and accounted for by Licensee and its
sublicensees,
as applicable, as a typical sale at the average gross sales price of the Licensed Product by
Licensee
or the sublicensee, as the case may be, in the market in which such transaction occurred.

     1.07 “License Fee” shall mean a fee paid to Licensee by a sublicensee for the privilege of
receiving a sublicense, which is neither based on Net Sales by the sublicensee nor deductible
from
royalties paid or payable to Licensee by the sublicensee for its Net Sales.

Article II. Grant of License.

     2.01 Exclusive License. Licensor agrees to grant and hereby does grant to Licensee
the

2

 

exclusive worldwide right and license to all of Licensor’s rights in and to the Licensed Patents,
including but not limited to the exclusive worldwide right and license to make, have made, use,
sell, import, export and otherwise dispose of the Licensed Products, and to practice the Licensed
Methods.

     2.02 Right to grant Sublicenses. The license granted to Licensee hereunder shall
include the exclusive right to grant sublicenses to third parties for the exercise of any or all
of the rights granted in the Licensee’s license in any territory constituting a country, portion
of a country, or countries of the world.

Article III. Royalties; Advances; Audit.

     3.01 Royalties.

     (a) Licensee shall pay Licensor Royalties at the royalty rate specified in Exhibit
B applied to
(i) Net Sales of Licensed Products by Licensee and its sublicensees and (ii) any License Fees
received
by Licensee on account of sublicenses.

     (b) Royalties shall be deemed earned when sales are made, but shall be due and payable
quarterly in United States dollars, within 90 days after the end of the fiscal quarter of
Licensee in
which the applicable sales were made. Only one Royalty shall be due per Licensed Product sold,
regardless of the number of Licensed Patents and/or claims that may apply or the number of
times a
Licensed Product may be used to practice Licensed Methods.

     (c) With each quarterly payment of Royalties, Licensee shall furnish a quarterly report to
Licensor setting forth its own and its sublicensees’ cumulative gross sales, permitted
deductions and
resulting Net Sales of the Licensed Products, License Fees and the Royalty payment due thereon
for
the applicable fiscal quarter. If no sales of Licensed Products were made in the quarter by
Licensee
or its sublicensees, the report shall so state.

     3.02 Advances.

     (a) Annual. Licensee shall pay Licensor annual advances (“Annual Advances”) against
earned Royalties in the amount of $25,000.00 each, to be paid on January 1 of each year,
retroactive
to January 1, 2000, for a period of five years ending December 31, 2004 (totaling
$125,000.00), or
until the first sale of a Licensed Product, whichever occurs first. Annual Advances shall be
deducted
from Royalties earned at any time during the term of this Agreement (or payable thereafter as
provided herein).

     (b) Milestone. Licensee shall also pay Licensor advances for each of the following
milestones against future earned Royalties (“Milestone Advances”), within 30 days after the
respective milestone is first reached during the term of this Agreement, in the following
amounts (up
to a maximum cumulative amount of $325,000.00): (1) $25,000.00 upon the first implant by
Licensor
of a Licensee VNS device in a patient in the pilot clinical study of VNS as a treatment for
obesity

3

 

(which milestone the parties acknowledge has been reached as of the date hereof), (2) $50,000.00
upon completion of a 30-patient pilot clinical study of VNS as a treatment for obesity, (3)
$100,000.00 upon completion of a pivotal or Phase III clinical study of VNS as a treatment for
obesity that would support a Premarket Approval (PMA) application to FDA and submission of
the results of that study as part of a PMA application submission to the FDA, and (d) $150,000.00
upon FDA approval of VNS for the treatment of obesity. A prerequisite for the payment of each
Milestone Advance, in addition to actual achievement of the respective milestone, is that Licensor
shall have performed the implant for milestone (1), and, except in the event of either his death
or a disability that prevents him from doing so, Licensor shall have been an active advisor and
clinical investigator in the achievement of each of milestones (2), (3) and (4). Milestone
Advances shall be deducted from Royalties earned at any time during the term of this Agreement (or
payable thereafter as provided herein).

     (c) Deductibility. To the extent that either or both the Annual Advances and Milestone
Advances cannot be deducted from earned Royalties because of an insufficiency of Net Sales of
Licensed Products, the non-deducted amounts of such advance payments shall not be refundable by
Licensor.

     3.03 Audit.

     (a) Licensee shall maintain books and records according to generally accepted accounting
principles bearing on its sales of the Licensed Products, and shall, on not less than 30 days’
advance
notice of Licensor’s intent to audit, make same available for inspection and audit on its own
premises
during Licensee’s regular business hours. Any such audit(s) shall be performed by a CPA
designated
and paid by Licensor(Licensor’s auditor), not more often than annually during the term of this
Agreement, with respect to applicable sales made in the preceding calendar year.

     (b) Licensee shall promptly pay any deficiency in Royalties payable to Licensor uncovered
by audit, with interest at an annual rate of 1% over the prime rate, calculated from the
date(s) the
underpaid amount(s) should have been paid. If the deficiency exceeds 10% of the Royalties
actually
earned for the year under audit, Licensee shall reimburse Licensor’s cost of the audit.
Licensor’s
agreement with its auditor shall require the auditor not to disclose to third parties
Confidential
Information of Licensee obtained from the audit, and Licensee may require Licensor’s auditor
to sign
a non-disclosure agreement to that effect prior to allowing the audit.

     3.04 Change of Control. In the event that Licensee undergoes a change in control
(measured
as a change in legal or beneficial ownership, or a combination thereof, by a single entity of
more than
50% of Licensee’s capital stock entitled to vote for the election of directors) from that
which existed
at the Effective Date, Licensor shall, upon the occurrence of the change of control, be within
60 days
after the change of control is effected, due in cash the difference between $450,000.00 and
the sum
of any Annual Advances or Milestone Advances that have been made as of the occurrence of the
change of control (such difference being the “Accelerated Change of Control Payment”). Upon
payment of the Accelerated Change of Control Payment, Licensor will no longer be entitled to
any
additional Annual Advances or Milestone Advances and a total of $450,000 (including any
Royalties

4

 

that have already been deducted as of the occurrence of the change of control) will be
deducted from Royalties earned at any time during the term of this Agreement (or payable
thereafter as provided herein).

Article IV. Prosecution and Maintenance of Licensed Patents.

     4.01 Prosecution. Licensee shall have the right to prosecute or have prosecuted
and bear the
entire cost of prosecuting the ‘396 Application, and all other applications among the Licensed
Patents,
including any applications for patent or counterpart applications Licensee may elect to file
or have
designated and Licensee shall pay all government fees designated for maintaining the pendency
of
such applications and of patents maturing therefrom.

     4.02 Notice. Licensor shall give Licensee notice of each and every Invention within 30
days
after conception thereof; and shall not make an Invention public without first having given
Licensee
both notice thereof and a reasonable opportunity to file a patent application on the
Invention.

Article V. Infringement.

     5.01 Of Patents of Third Parties by Licensee or Its Sublicensees. Licensee and/or its
sublicensees shall defend at their own expense all suits brought against them for infringement
of third
party patents by their respective manufacture, use, sale, or other disposition of Licensed
Products.
In no event shall Licensee enter into a settlement containing terms purporting to affect the
validity
or scope of a Licensed Patent without obtaining prior written consent of Licensor, which shall
not
be withheld unreasonably.

     5.02 Of the Licensed Patents by Third Parties. During the term of this Agreement, Licensee
shall have the option but not the obligation, at its own expense, to investigate and prosecute
infringements of the Licensed Patents. Licensee shall be entitled to the entirety of any
recovery by
way of settlement or award of money damages based on a claim of infringement of a Licensed
Patent
(collectively, “Claim”), provided, however, that any such recovery shall be treated as Net
Sales and
subject to Licensor Royalties. If Licensee declines to take action against an alleged
infringer, it shall
so notify Licensor who shall then have the right to prosecute the infringer at its own
expense, and in
that event, Licensor and Licensee shall share equally the amount of the recovery, if any,
after
deduction of Licensor’s costs, including attorney fees, incurred for such prosecution.

     5.03 Joinder and Cooperation of Licensee. Licensee may join Licensor as a party
plaintiff in
any suit or counterclaim instituted by Licensee for infringement or in defense of validity of
a Licensed
Patent, provided that Licensee shall indemnify and hold harmless Licensor from and against any
damages, losses, awards, costs, and expenses (including attorney’s fees) accrued as a result
of or
arising from or in connection with such joinder. Whether joined or not, Licensor agrees upon
Licensee’s request to provide reasonable assistance and cooperation to Licensee in advancing a
Claim
or in defending the validity of a Licensed Patent, subject only to Licensee’s reimbursement or
direct
payment of costs incurred by Licensor for or in connection with such assistance and
cooperation.

5

 

     5.04
Non-refundable Royalties; Adjustment. Licensee shall not be entitled to a
refund of Royalties paid to Licensor, but if one or more (but less than all) of the Licensed
Patents is held by final decision of a court of last resort (as the result of an appeal or a
failure to timely prosecute an appeal) to be invalid or unenforceable, Licensor and Licensee shall
promptly negotiate an equitable downward adjustment of the royalty rate as to the remaining patents
which shall apply to future Net Sales and Exhibit B shall be modified in writing
accordingly.

Article VI. Representations and Warranties.

     6.01 By Licensor. Licensor represents and warrants to Licensee that, as of the
Effective Date
of this Agreement:

     (a) Licensor owns an undivided interest in the Licensed Patents and has complete power and
authority to enter into this Agreement and to grant the rights and licenses granted herein to
Licensee.

     (b) Licensor is not aware of any information which is material to the patentability or
validity
of the ‘396 application that he not already brought to the attention of Licensee.

     (c) Licensor has not entered into any agreement or understanding with any third party that
conflicts with this Agreement or the rights and licenses granted herein to Licensee.

     6.02 By Licensee. Licensee represents and warrants to Licensor that, as of the
Effective Date
of this Agreement:

     (a) Licensee has complete power and authority to enter into this Agreement, and to accept
and perform all of its other obligations on the terms and conditions set forth herein.

     (b) Licensee does not require any approval from any third party to enter into this
Agreement.

     (c) Licensee’s entry into this Agreement will not conflict with any other agreement or
understanding it has with a third party.

     (d) Licensee will defend, indemnify and hold harmless Licensor from and against any liability
for manufacture, use, sale, or other activity relating to the Licensed Products or practice of
the
Licensed Methods, including without limitation all costs, fees (including attorney’s fees),
awards,
damages, fines, and penalties finally awarded against Licensee or Licensor for any Claim of
personal
injury, death, emotional distress, property damage, or any other casualty or risk whatsoever.
Licensor
shall promptly notify Licensee of any Claim or communication relating thereto made to
Licensor, shall
furnish reasonable assistance and information to Licensee for defense or settlement of such
claim, and
shall give Licensee authority to assume control of the defense or settlement of the Claim
including
the right to appoint counsel to implement such defense or settlement.

     6.03 Disclaimers. Nothing contained in this Agreement shall constitute a
representation or
warranty by Licensor that:

6

 

     (a) a
patent will issue from any application encompassed within the Licensed Patents or Improvement Patents; or

     (b) the Licensed Patents are valid or enforceable; or

     (c) the manufacture, use, sale, or other activity relating to the Licensed Products or
practice
of the Licensed Methods will be free from infringement of third party patent(s).

Article VII. Term and Termination.

     7.01 Term. This Agreement shall commence on the Effective Date, and shall remain in
force
until the last Licensed Patent expires or is held invalid or unenforceable, unless terminated
earlier as provided herein.

     7.02 Termination.

     (a) Licensor or Licensee may terminate this Agreement and the licenses and rights granted
to Licensee herein by notice given to the other at any time after 90 days from date of notice
to the
other of a breach which has not been cured prior to the termination notice; provided, however,
if the
breach is other than a failure to pay money and cannot reasonably be cured within 90 days but
the
party charged with having committed the breach has taken reasonable steps to effect a cure
within
that period and is acting with diligence to complete the cure, then the notice period for
breach shall
be extended until the cure is effected, not to exceed an additional 60 days. The licenses and
rights
granted herein shall terminate upon termination of this Agreement.

     (b) Upon termination of this Agreement, Licensee and its sublicensees shall have the right to
sell or otherwise dispose of its and their then remaining inventory of the Licensed Products,
subject
to compliance with all applicable provisions of Article III above, including the continued
payment of
Royalties.

     7.03 Surviving Provisions. The provisions of Articles III, V (to the extent of any then-remaining obligations of the Parties), VI, section 7.02(b), and sections 8.01, 8.03, 8.05, and
8.06,
shall survive expiration or termination of this Agreement.

Article VIII. General.

     8.01 Notices. Any and all notices or other communications required or permitted
to be given under any of the provisions of this Agreement shall be in writing and shall be deemed
to have been duly given when personally delivered or the earlier of (i) 6 business days after the
mailing thereof (postage prepaid, first class mail) and (ii) the actual receipt thereof if
delivered by facsimile transmission or if mailed by first class registered mail, return receipt
requested, addressed:

7

 

	 	 	 	 	 
	 

	 	If to Licensor:
	 	Mitchell S. Roslin, M.D.
	 

	 	 	 	149 Beach 144 Street
	 

	 	 	 	Far Rockaway, NY 11694
	 
	 	 	 	 
	 

	 	With copy to:
	 	Matthew I. Roslin, Esq.
	 

	 	 	 	Executive Vice President
	 

	 	 	 	MED3000 Group, Inc.
	 

	 	 	 	Foster Plaza 10
	 

	 	 	 	680 Andersen Drive
	 

	 	 	 	Pittsburgh, PA 15220
	 

	 	 	 	(Facsimile No: 412-937-9221)
	 
	 	 	 	 
	 

	 	If to Licensee:
	 	Cyberonics, Inc.
	 

	 	 	 	16511 Space Center Boulevard, Suite 600
	 

	 	 	 	Houston, TX 77058 
Attention: Robert
P. Cummins
	 

	 	 	 	(Facsimile No: 281-218-9332)
	 
	 	 	 	 
	 

	 	With copy to:
	 	Blank Rome Comisky & McCauley LLP
	 

	 	 	 	900 17th Street, N.W., Suite 1000
	 

	 	 	 	Washington, D.C. 20006
	 

	 	 	 	Attention: Donald R. Greene, Esq.
	 

	 	 	 	(Facsimile No: 202-463-6915)

or to such changed address as shall have been designated by notice.

     8.02 Assignment. Licensor shall not assign any rights or delegate any duties under this
Agreement. Except for an assignment to a successor in interest to Licensee’s business to which
this
Agreement relates, Licensee shall not assign this Agreement without the prior written consent
of
Licensor, which shall not be unreasonably withheld or delayed. Except as otherwise provided
herein,
this Agreement shall be binding on and inure to the benefit of each Party and their respective
heirs,
personal representatives, executors, successors and assigns.

     8.03 Confidentiality. Licensor shall protect and preserve the confidentiality of all
Licensee’s
Confidential Information which Licensor may learn in the course of performance under this
Agreement, and Licensor agrees not to disclose any such Confidential Information to any third
party
or use it for his own benefit or the benefit of any third party without the prior written
consent of an
authorized officer of Licensee.

     8.04 Cooperation. Each Party shall cooperate, and shall take such further action and
shall
execute and deliver such further documents as may be reasonably requested by the other Party
in
order to carry out the provisions and purposes of this Agreement.

     8.05 Construction and Law. This Agreement shall be governed and construed in accordance
with the laws of the State of Texas, U.S.A. applicable to contracts made and to be performed
therein.

8

 

Article and section headings contained in this Agreement are for purposes of convenience of
reference only, and are not intended to define or limit the contents of the respective Articles or
sections or to be otherwise used for construction of the Agreement.

     8.06 Entire Agreement. This Agreement embodies the entire understanding of the Parties
respecting the subject matter hereof, and supersedes all prior and contemporaneous agreements
between them respecting that subject matter. This Agreement may not be modified except by a written
agreement specifically referring to this Agreement and signed by both Parties. No waiver of any
breach or default hereunder shall be considered valid unless given in writing and signed by the
Party giving such waiver, and no waiver shall be deemed a waiver of any other contemporaneous or
subsequent breach or default.

     IN WITNESS WHEREOF, the parties have executed this Agreement or caused it to be executed by
their respective duly authorized representatives, in one or more counterparts, all of which taken
together shall be deemed one original, as of the Effective Date hereof.

	 	 	 	 	 	 	 
	 	 	LICENSEE:	 	 
	 
	 	 	 	 	 	 
	 	 	CYBERONICS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By
	 	/s/ Pamela B. Westbrook
 

Pamela B. Westbrook. Vice President,
	 	 
	 

	 	 	 	Finance and Administration &
CFO	 	 
	 
	 	 	 	 	 	 
	 	 	LICENSOR:	 	 
	 
	 	 	 	 	 	 
	 	 	/s/ Mitchell S. Roslin	 	 
	 	 	 	 	 
	 	 	Mitchell S. Roslin, M.D.	 	 

9

 

EXHIBIT A 

 LICENSED PATENTS

•  U.S. Patent Application Serial No. 09/346,396, filed July 1, 1999 in the U.S. Patent and
Trademark Office (PTO).

•  Patent
Cooperation Treaty (PCT) Application Serial No. US/00/____ , filed June 30,
2000 in United States Receiving Office, based on U.S. Serial No. 09/346,396.

10

 

EXHIBIT B 

 ROYALTY RATE

The royalty rate payable under Article III
of this Agreement shall be:

1.0 % on the first US$10 million of Net Sales of the Licensed Products; and 0.5% of Net Sales of
the Licensed Products thereafter.

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]